This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2015 Mar;12(3):126.

doi: 10.1038/nrurol.2015.27. Epub 2015 Feb 17.

Prostate cancer: Hypofractionation not associated with reduced toxicity

PMID: 25687269
DOI: 10.1038/nrurol.2015.27

Comment

Prostate cancer: Hypofractionation not associated with reduced toxicity

Rebecca Kelsey. Nat Rev Urol. 2015 Mar.

. 2015 Mar;12(3):126.

doi: 10.1038/nrurol.2015.27. Epub 2015 Feb 17.

Author

PMID: 25687269
DOI: 10.1038/nrurol.2015.27

No abstract available

PubMed Disclaimer

Comment on

Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
Aluwini S, Pos F, Schimmel E, van Lin E, Krol S, van der Toorn PP, de Jager H, Dirkx M, Alemayehu WG, Heijmen B, Incrocci L. Aluwini S, et al. Lancet Oncol. 2015 Mar;16(3):274-83. doi: 10.1016/S1470-2045(14)70482-6. Epub 2015 Feb 3. Lancet Oncol. 2015. PMID: 25656287 Clinical Trial.

References

1. Lancet Oncol. 2015 Mar;16(3):274-83 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information